Pivotal Phase 3 Data for KEYTRUDA (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

09.02.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant ...

Related Keywords

Canada ,United States ,London ,City Of ,United Kingdom ,American ,Peter Schmid ,Roy Baynes ,Instagram ,Merck Research Laboratories ,Linkedin ,Twitter ,Centre For Experimental Cancer Medicine ,Statement Of Merck Co Inc ,Merck Co Inc ,Exchange Commission ,Youtube ,Facebook ,Barts Cancer Institute ,Experimental Cancer Medicine ,Merck Research ,New England Journal ,Additional Data From ,Combined Positive Score ,Triple Negative Breast Cancer ,African American ,Neck Squamous Cell ,Bacillus Calmette Guerin ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Patients With Multiple ,Looking Statement ,Securities Litigation Reform Act ,Merck Co ,